These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26752281)

  • 1. No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.
    Raymond S; Nicot F; Carcenac R; Jeanne N; Cazabat M; Requena M; Cuzin L; Delobel P; Izopet J;
    AIDS; 2016 Mar; 30(6):965-8. PubMed ID: 26752281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
    McGovern RA; Symons J; Poon AF; Harrigan PR; van Lelyveld SF; Hoepelman AI; van Ham PM; Dong W; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2013 Sep; 68(9):2007-14. PubMed ID: 23677920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
    Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
    J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.
    Genebat M; de Pablo-Bernal RS; Pulido I; Jiménez-Mejías ME; Martínez O; Pacheco YM; Raffi-El-Idrissi Benhia M; Abad MA; Ruiz-Mateos E; Leal M
    Antiviral Res; 2015 Sep; 121():94-6. PubMed ID: 26122170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
    Swenson LC; Dong WW; Mo T; Demarest J; Chapman D; Ellery S; Heera J; Valdez H; Poon AF; Harrigan PR
    Clin Infect Dis; 2013 Jun; 56(11):1659-66. PubMed ID: 23429552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.
    Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Thielen A; Jensen MA; Knapp DJ; Chapman D; Portsmouth S; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    Clin Infect Dis; 2011 Oct; 53(7):732-42. PubMed ID: 21890778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
    van Lelyveld SF; Symons J; van Ham P; Connell BJ; Nijhuis M; Wensing AM; Hoepelman AI
    Int J Antimicrob Agents; 2016 Jan; 47(1):84-90. PubMed ID: 26585497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
    Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
    Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
    Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy.
    Raymond S; Saliou A; Delobel P; Cazabat M; Pasquier C; Jeanne N; Sauné K; Massip P; Marchou B; Izopet J
    J Antimicrob Chemother; 2014 Sep; 69(9):2527-30. PubMed ID: 24840625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological failure of patients on maraviroc-based antiretroviral therapy.
    Raymond S; Maillard A; Amiel C; Peytavin G; Trabaud MA; Desbois D; Bellecave P; Delaugerre C; Soulie C; Marcelin AG; Descamps D; Izopet J;
    J Antimicrob Chemother; 2015; 70(6):1858-64. PubMed ID: 25700719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [At what time and with which combinations should maraviroc be indicated in the new antiretroviral treatment scenario?].
    Leal M; Camacho A; Genebat M; Rivero A
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():34-9. PubMed ID: 19133220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment.
    Genebat M; Pulido I; Romero-Sánchez MC; González-Serna A; Ferrando-Martínez S; Machmach K; Pacheco YM; Muñoz-Fernández MÁ; Ruiz-Mateos E; Leal M
    Antiviral Res; 2012 Sep; 95(3):207-11. PubMed ID: 22750308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune recovery and T cell subset analysis during effective treatment with maraviroc.
    Cossarini F; Galli A; Galli L; Bigoloni A; Salpietro S; Vinci C; Della Torre L; Gianotti N; Spagnuolo V; Lazzarin A; Castagna A; Nozza S
    J Antimicrob Chemother; 2012 Oct; 67(10):2474-8. PubMed ID: 22678730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.